Comparative Pharmacology
Head-to-head clinical analysis: DUAKLIR PRESSAIR versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUAKLIR PRESSAIR versus HICON.
DUAKLIR PRESSAIR vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dual bronchodilator combining a long-acting muscarinic antagonist (aclidinium) and a long-acting beta2-agonist (formoterol). Aclidinium inhibits acetylcholine at M3 receptors, reducing bronchoconstriction; formoterol stimulates beta2-adrenergic receptors, relaxing airway smooth muscle.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
1 inhalation (aclidinium 400 mcg / formoterol 12 mcg) twice daily.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal half-life 5.0–6.5 hours (aclidinium); steady-state reached within 2 days; no accumulation at therapeutic doses
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal (55% as unchanged aclidinium; 20% as metabolites); biliary/fecal (33% as metabolites and parent)
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic/Beta2-Agonist Combination
Anticholinergic